Analysis of Genetically Regulated Gene Expression Identifies a Prefrontal PTSD Gene, SNRNP35, Specific to Military Cohorts.
Animals
Case-Control Studies
Cohort Studies
Dexamethasone
/ pharmacology
Down-Regulation
/ drug effects
Gene Expression Regulation
Gene Regulatory Networks
Genetic Predisposition to Disease
Humans
Leukocytes
/ cytology
Male
Mice
Mice, Inbred C57BL
Military Personnel
Prefrontal Cortex
/ metabolism
RNA Interference
RNA, Small Interfering
/ metabolism
Repressor Proteins
/ blood
Ribonucleoproteins, Small Nuclear
/ antagonists & inhibitors
Stress Disorders, Post-Traumatic
/ blood
GWAS
PTSD
blood
civilian
glucocorticoid
military
prefrontal cortex
sex
splicing
transcriptomic imputation
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
02 06 2020
02 06 2020
Historique:
received:
06
03
2019
revised:
07
10
2019
accepted:
09
05
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
4
5
2021
Statut:
ppublish
Résumé
To reveal post-traumatic stress disorder (PTSD) genetic risk influences on tissue-specific gene expression, we use brain and non-brain transcriptomic imputation. We impute genetically regulated gene expression (GReX) in 29,539 PTSD cases and 166,145 controls from 70 ancestry-specific cohorts and identify 18 significant GReX-PTSD associations corresponding to specific tissue-gene pairs. The results suggest substantial genetic heterogeneity based on ancestry, cohort type (military versus civilian), and sex. Two study-wide significant PTSD associations are identified in European and military European cohorts; ZNF140 is predicted to be upregulated in whole blood, and SNRNP35 is predicted to be downregulated in dorsolateral prefrontal cortex, respectively. In peripheral leukocytes from 175 marines, the observed PTSD differential gene expression correlates with the predicted differences for these individuals, and deployment stress produces glucocorticoid-regulated expression changes that include downregulation of both ZNF140 and SNRNP35. SNRNP35 knockdown in cells validates its functional role in U12-intron splicing. Finally, exogenous glucocorticoids in mice downregulate prefrontal Snrnp35 expression.
Identifiants
pubmed: 32492425
pii: S2211-1247(20)30693-8
doi: 10.1016/j.celrep.2020.107716
pmc: PMC7359754
mid: NIHMS1600582
pii:
doi:
Substances chimiques
RNA, Small Interfering
0
Repressor Proteins
0
Ribonucleoproteins, Small Nuclear
0
SNRNP35 protein, human
0
ZNF140 protein, human
0
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
107716Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR002542
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH117292
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH107666
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002541
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH118278
Pays : United States
Organisme : NIMH NIH HHS
ID : P50 MH115874
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH109536
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH124839
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH101820
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH109539
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH106595
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK020595
Pays : United States
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests J.W.S. is an unpaid member of the Bipolar/Depression Research Community Advisory Panel of 23andMe. D.J.S. has received research grants and/or consultancy honoraria from Biocodex, Lundbeck, and Sun. R.Y. is a co-inventor of the following patent: “Genes associated with posttraumatic-stress disorder, WO 2010029176 A1.” I.L. has been a consultant for ARMGO Pharmaceuticals, Sunovion Pharmaceuticals, and Trimaran Pharma. K.J.R. has received consulting income from Alkermes and is on scientific advisory boards for Janssen, Verily, and Resilience Therapeutics. He has also received sponsored research support from Takeda and Brainsway. N.P.D. has held a part-time paid position at Cohen Veteran Bioscience. He has also been a consultant for Sunovion Pharmaceuticals.